© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 91301 refers to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, specifically designed to combat coronavirus disease (COVID-19). This vaccine utilizes a novel approach by employing messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), which is a cutting-edge technology in vaccine development. The mRNA contained in the vaccine encodes the spike protein of the SARS-CoV-2 virus, which is critical for the virus's ability to infect human cells. Upon administration, the mRNA instructs the body's cells to produce copies of the spike protein, which the immune system identifies as foreign. This triggers an immune response, leading to the production of antibodies that can recognize and neutralize the virus if the individual is exposed in the future. The vaccine is preservative-free and is administered intramuscularly in a dosage of 100 mcg per 0.5 mL. It is important to note that this code specifically reports the supply of the vaccine itself, and the actual injection of the vaccine is reported separately using the appropriate administration code, which varies based on the dose given. The vaccine is part of a two-dose series, with a third dose now available for certain populations as recommended by the Centers for Disease Control and Prevention (CDC).
© Copyright 2025 Coding Ahead. All rights reserved.
The COVID-19 vaccine, represented by CPT® Code 91301, is indicated for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which can lead to coronavirus disease (COVID-19). The vaccine is particularly important for individuals at risk of severe illness, hospitalization, or death due to COVID-19. It is recommended for use in populations identified by health authorities, including those who may require a third dose as per CDC guidelines.
The administration of the COVID-19 vaccine involves several key procedural steps to ensure safety and efficacy. First, the healthcare provider prepares the vaccine by ensuring that it is stored at the appropriate temperature and is not expired. The vaccine is then drawn into a syringe, ensuring that the correct dosage of 100 mcg per 0.5 mL is accurately measured. Next, the provider selects an appropriate site for intramuscular injection, typically the deltoid muscle of the upper arm. The injection site is cleaned with an antiseptic wipe to minimize the risk of infection. Following this, the vaccine is injected intramuscularly, and the syringe is disposed of in a sharps container to ensure safety. After the injection, the patient is monitored for a brief period to observe for any immediate adverse reactions, which is a standard practice for vaccine administration.
After the administration of the COVID-19 vaccine, patients are typically advised to remain at the healthcare facility for a short period to monitor for any immediate side effects, which may include mild reactions such as soreness at the injection site, fatigue, headache, or low-grade fever. These reactions are generally short-lived and indicate that the body is building protection against the virus. Patients are also provided with information regarding potential side effects that may occur in the days following vaccination and are encouraged to report any unusual or severe reactions. It is important for individuals to follow up with their healthcare provider for any additional doses as recommended, particularly for those who are eligible for a third dose as per CDC guidelines. Overall, the post-procedure care focuses on ensuring patient safety and encouraging adherence to the vaccination schedule.
| Short Descr | SARSCOV2 VAC 100MCG/0.5ML IM | Medium Descr | SARSCOV2 VACCINE 100 MCG/0.5 ML IM USE | Long Descr | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use | Status Code | Not Valid for Medicare Purposes | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Non-Covered Service, not paid under OPPS | Berenson-Eggers TOS (BETOS) | none | MUE | Not applicable/unspecified. |
| XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | CR | Catastrophe/disaster related | SL | State supplied vaccine |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2025-01-01 | Deleted | First appearance of code deletion in codebook. |
| 2024-01-01 | Note | First appearnce of 2022 guideline changes in codebook. |
| 2023-11-01 | Deleted | Code deleted. See 91318, 91319, 91320, 91321, 91322. |
| 2023-04-18 | Note | Changes made to dosing information |
| 2023-04-18 | Note | AMA guidelines changed to include 0141A, 0142A. Published to website 2023-05-01. Received FDA approval effective retroactively to 2023-04-18. |
| 2023-04-18 | Note | These codes (included in the guidelines) are no longer authorized for use in the United States: 0011A, 0012A, 0013A, 0064A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A. |
| 2023-04-18 | Note | No longer authorized for use in the United States. |
| 2023-01-01 | Note | First appearance of guideline change(s) in codebook. |
| 2022-12-08 | Note | AMA Guideline changed. 0164A received FDA approval. |
| 2022-11-16 | Note | AMA guideline changed to include 0164A effective upon receiving Emergency Use Authorization or approval from the FDA |
| 2022-10-12 | Note | AMA Guideline changed. 0134A (12–17 yrs) and 0144A received FDA approval. |
| 2022-08-31 | Note | AMA guideline changed to include 0134A, 0144A effective upon receiving emergency Use Authorization or approval from the FDA. |
| 2022-08-31 | Note | AMA Guideline changed. 0134A (18 yrs and older) received FDA approval effective immediately. |
| 2022-08-31 | Note | Changes made to vaccine name, product & dosing information, & patient age to (12+). |
| 2022-06-17 | Note | AMA Guideline changed. 0111A, 0112A received FDA approval. |
| 2022-06-17 | Note | AMA guideline changed to include 0113A. Published to website 2022-07-06. Received FDA approval effective retroactively to 2022-06-17. |
| 2022-06-17 | Note | AMA Guideline changed to include 0091A, 0092A, 0093A, 0113A published on website 2022-07-06. FDA approval received retroactively to 2022-06-17. |
| 2022-05-19 | Note | AMA guideline changed to include 0111A, 0112A effective upon receiving Emergency Use Authorization or approval from the FDA. |
| 2022-05-19 | Note | AMA guideline changed to include 0111A, 0112A effective upon receiving Emergency Use Authorization or approval from the FDA. |
| 2022-03-29 | Note | AMA Guideline changed. 0094A received FDA approval. |
| 2022-03-07 | Note | AMA guideline changed to include 0094A effective upon receiving Emergency Use Authorization or approval from the FDA. |
| 2022-01-01 | Note | Grammar correction |
| 2022-01-01 | Added | First appearance of code in codebook. |
| 2022-01-01 | Changed | Code description changed. |
| 2021-10-20 | Note | AMA Guideline changed. 0064A received FDA approval. |
| 2021-09-03 | Note | AMA guideline changed to include 0064A effective upon receiving Emergency Use Authorization or approval from the FDA. |
| 2021-08-12 | Note | AMA guideline changed to include 0013A, 2021-08-16. FDA approval received. Effective retroactively to 2021-08-12 |
| 2021-01-01 | Added | First appearance of code in CPT® Code Set. |
| 2020-12-18 | Note | AMA Guideline changed. 0011A, 0012A received FDA approval. |
| 2020-12-18 | Added | FDA authorization granted |
| 2020-11-10 | Added | Published on AMA website. Effective upon receiving emergency Use Authorization or approval from the FDA. |
| 2020-11-10 | Note | Published on AMA website. Codes 0011A, 0012A Effective upon receiving mergency Use Authorization or approval from the FDA. |
Get instant expert-level medical coding assistance.